MX2022006536A - Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderan al tratamiento con un inhibidor de fgfr. - Google Patents
Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderan al tratamiento con un inhibidor de fgfr.Info
- Publication number
- MX2022006536A MX2022006536A MX2022006536A MX2022006536A MX2022006536A MX 2022006536 A MX2022006536 A MX 2022006536A MX 2022006536 A MX2022006536 A MX 2022006536A MX 2022006536 A MX2022006536 A MX 2022006536A MX 2022006536 A MX2022006536 A MX 2022006536A
- Authority
- MX
- Mexico
- Prior art keywords
- fgfr
- responsive
- treatment
- cancer patients
- mutant gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
En la presente descripción se describen métodos para identificar un paciente con cáncer que responderá al tratamiento con un inhibidor del receptor del factor de crecimiento de fibroblastos (FGFR) y métodos para tratar pacientes con cáncer; los métodos implican evaluar una muestra biológica del paciente para detectar la presencia de uno o más mutantes de FGFR a partir de un panel de genes mutantes de FGFR; en la presente descripción se describen, además, kits e iniciadores para identificar la presencia de uno o más genes mutantes de FGFR en una muestra biológica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056159P | 2014-09-26 | 2014-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006536A true MX2022006536A (es) | 2022-07-11 |
Family
ID=54337343
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003954A MX2017003954A (es) | 2014-09-26 | 2015-09-18 | Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr. |
| MX2022006536A MX2022006536A (es) | 2014-09-26 | 2017-03-24 | Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderan al tratamiento con un inhibidor de fgfr. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003954A MX2017003954A (es) | 2014-09-26 | 2015-09-18 | Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr. |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US20160090633A1 (es) |
| EP (2) | EP4063516A1 (es) |
| JP (3) | JP6766037B2 (es) |
| KR (2) | KR20220162823A (es) |
| CN (2) | CN107002141B (es) |
| AR (1) | AR102345A1 (es) |
| AU (2) | AU2015321626B2 (es) |
| BR (1) | BR112017006088A2 (es) |
| CA (1) | CA2962075A1 (es) |
| CO (1) | CO2017003528A2 (es) |
| CR (1) | CR20170104A (es) |
| DK (1) | DK3198033T3 (es) |
| EA (1) | EA037920B1 (es) |
| EC (1) | ECSP17025787A (es) |
| ES (1) | ES2912567T3 (es) |
| GT (1) | GT201700059A (es) |
| HR (1) | HRP20220496T1 (es) |
| HU (1) | HUE058219T2 (es) |
| IL (2) | IL251264B (es) |
| JO (1) | JO3681B1 (es) |
| LT (1) | LT3198033T (es) |
| MA (1) | MA40761B1 (es) |
| MX (2) | MX2017003954A (es) |
| MY (1) | MY194567A (es) |
| NI (1) | NI201700035A (es) |
| PH (1) | PH12017500556A1 (es) |
| PL (1) | PL3198033T3 (es) |
| PT (1) | PT3198033T (es) |
| RS (1) | RS63178B1 (es) |
| SG (1) | SG11201702381QA (es) |
| SI (1) | SI3198033T1 (es) |
| SV (1) | SV2017005415A (es) |
| TW (1) | TWI706136B (es) |
| UA (1) | UA122564C2 (es) |
| UY (1) | UY36325A (es) |
| WO (1) | WO2016048833A2 (es) |
| ZA (1) | ZA201702899B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014051022A1 (ja) | 2012-09-27 | 2014-04-03 | 中外製薬株式会社 | Fgfr3融合遺伝子およびそれを標的とする医薬 |
| JP6731254B2 (ja) * | 2014-01-24 | 2020-07-29 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| AU2015238301B2 (en) | 2014-03-26 | 2020-06-25 | Astex Therapeutics Ltd | Combinations |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| KR20180118719A (ko) * | 2016-03-04 | 2018-10-31 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| JOP20190280A1 (ar) | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| KR20210064274A (ko) * | 2018-09-21 | 2021-06-02 | 얀센 파마슈티카 엔.브이. | 담관암종의 치료 |
| MX2021011926A (es) | 2019-03-29 | 2021-11-03 | Janssen Pharmaceutica Nv | Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial. |
| BR112021019203A2 (pt) | 2019-03-29 | 2021-11-30 | Janssen Pharmaceutica Nv | Inibidores de tirosina quinase fgfr para o tratamento de carcinoma urotelial |
| MX2021014524A (es) * | 2019-05-31 | 2022-05-19 | Qed Therapeutics Inc | Metodos para tratar canceres del sistema urinario. |
| CN110241183B (zh) * | 2019-06-13 | 2022-10-28 | 南京世和基因生物技术股份有限公司 | 一种fgfr融合基因的检测方法、试剂盒以及探针库 |
| WO2021050100A1 (en) * | 2019-09-09 | 2021-03-18 | Zepto Life Technology, LLC | Systems and methods for detecting genetic variation in nucleic acids |
| BR112022005224A2 (pt) | 2019-09-26 | 2022-06-14 | Janssen Pharmaceutica Nv | Uso de inibidores de fgfr em cânceres alterados geneticamente por fgfr para melhorar a resposta do paciente a inibidores de ponto de verificação imune em configurações de tratamento sequenciais |
| KR20220140781A (ko) | 2020-02-12 | 2022-10-18 | 얀센 파마슈티카 엔.브이. | 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제 |
| TW202140012A (zh) | 2020-02-12 | 2021-11-01 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑 |
| CA3175356A1 (en) * | 2020-04-15 | 2021-10-21 | Jared LOPES | Immunostimulatory agents in combination with angiogenesis inhibitors |
| CN111440790A (zh) * | 2020-05-08 | 2020-07-24 | 公安部物证鉴定中心 | 唾液斑迹dna和rna同时提取的方法 |
| WO2022053697A1 (en) | 2020-09-14 | 2022-03-17 | Janssen Pharmaceutica Nv | Fgfr inhibitor combination therapies |
| CN112143815B (zh) * | 2020-11-25 | 2021-02-26 | 江苏申基生物科技有限公司 | 一种用于检测人fgfr2基因融合突变的核酸组合物、试剂盒及检测方法 |
| TW202313038A (zh) | 2021-05-19 | 2023-04-01 | 比利時商健生藥品公司 | 用於治療晚期實性瘤之ｆｇｆｒ酪胺酸激酶抑制劑 |
| TW202333720A (zh) | 2021-10-12 | 2023-09-01 | 美商塔里斯生物醫學有限責任公司 | 用於膀胱內施用的厄達替尼調配物及系統 |
| TW202400174A (zh) | 2022-02-18 | 2024-01-01 | 美商塔里斯生物醫學有限責任公司 | 用於膀胱內施用的Erdafitinib調配物及滲透系統 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8101359B2 (en) * | 2002-10-01 | 2012-01-24 | Epigenomics Ag | Method for determining risk of relapse of breast cancer following tamoxifen adjuvant therapy |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP1659175A1 (en) * | 2004-11-18 | 2006-05-24 | Institut Curie | Alterations in seborrheic keratoses and their applications |
| BRPI0611375A2 (pt) | 2005-05-23 | 2010-08-31 | Novartis Ag | formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona |
| US20090247576A1 (en) * | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
| WO2007067968A2 (en) | 2005-12-08 | 2007-06-14 | Novartis Ag | Effects of inhibitors of fgfr3 on gene transcription |
| EP1918376A1 (en) | 2006-11-03 | 2008-05-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| US8071338B2 (en) * | 2007-08-08 | 2011-12-06 | Roche Molecular Systems, Inc. | Suppression of amplification using an oligonucleotide and a polymerase significantly lacking 5′-3′ nuclease activity |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| GB201020179D0 (en) * | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN102293770A (zh) * | 2011-05-25 | 2011-12-28 | 温州医学院 | 新型成纤维细胞生长因子受体酪氨酸激酶抑制剂 |
| CN102319224B (zh) * | 2011-07-27 | 2013-03-20 | 赛乐医药科技(上海)有限公司 | 复方甲氧那明的速释－缓释渗透泵制剂 |
| WO2013026027A1 (en) * | 2011-08-18 | 2013-02-21 | Nestec S.A. | Compositions and methods for detecting allelic variants |
| US20130096021A1 (en) * | 2011-09-27 | 2013-04-18 | Arul M. Chinnaiyan | Recurrent gene fusions in breast cancer |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| WO2013088191A1 (en) * | 2011-12-12 | 2013-06-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3 |
| MX349120B (es) * | 2012-02-28 | 2017-07-12 | Astellas Pharma Inc | Compuesto heterociclico aromatico que contiene nitrogeno. |
| US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| GB201209609D0 (en) * | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| CN104619840A (zh) * | 2012-07-05 | 2015-05-13 | 日本国立癌症研究中心 | Fgfr2融合基因 |
| EP2877854B1 (en) * | 2012-07-24 | 2022-09-07 | The Trustees of Columbia University in the City of New York | Fgfr-tacc fusion proteins and methods thereof |
| RU2015102194A (ru) * | 2012-07-27 | 2016-09-20 | Дженентек, Инк. | Способы лечения связанных с fgfr3 состояний |
| WO2014051022A1 (ja) * | 2012-09-27 | 2014-04-03 | 中外製薬株式会社 | Fgfr3融合遺伝子およびそれを標的とする医薬 |
| US11230589B2 (en) * | 2012-11-05 | 2022-01-25 | Foundation Medicine, Inc. | Fusion molecules and uses thereof |
| WO2014113729A2 (en) * | 2013-01-18 | 2014-07-24 | Foundation Mecicine, Inc. | Methods of treating cholangiocarcinoma |
-
2015
- 2015-09-18 ES ES15782109T patent/ES2912567T3/es active Active
- 2015-09-18 MA MA40761A patent/MA40761B1/fr unknown
- 2015-09-18 KR KR1020227040649A patent/KR20220162823A/ko not_active Application Discontinuation
- 2015-09-18 MY MYPI2017700955A patent/MY194567A/en unknown
- 2015-09-18 RS RS20220400A patent/RS63178B1/sr unknown
- 2015-09-18 PT PT157821091T patent/PT3198033T/pt unknown
- 2015-09-18 US US14/858,627 patent/US20160090633A1/en not_active Abandoned
- 2015-09-18 EP EP22156319.0A patent/EP4063516A1/en active Pending
- 2015-09-18 BR BR112017006088A patent/BR112017006088A2/pt active Search and Examination
- 2015-09-18 CN CN201580064601.1A patent/CN107002141B/zh active Active
- 2015-09-18 CR CR20170104A patent/CR20170104A/es unknown
- 2015-09-18 MX MX2017003954A patent/MX2017003954A/es unknown
- 2015-09-18 HU HUE15782109A patent/HUE058219T2/hu unknown
- 2015-09-18 PL PL15782109.1T patent/PL3198033T3/pl unknown
- 2015-09-18 JP JP2017516458A patent/JP6766037B2/ja active Active
- 2015-09-18 EP EP15782109.1A patent/EP3198033B1/en active Active
- 2015-09-18 LT LTEPPCT/US2015/050996T patent/LT3198033T/lt unknown
- 2015-09-18 HR HRP20220496TT patent/HRP20220496T1/hr unknown
- 2015-09-18 SI SI201531836T patent/SI3198033T1/sl unknown
- 2015-09-18 CN CN202111247854.6A patent/CN113957146A/zh active Pending
- 2015-09-18 AU AU2015321626A patent/AU2015321626B2/en active Active
- 2015-09-18 SG SG11201702381QA patent/SG11201702381QA/en unknown
- 2015-09-18 UA UAA201704090A patent/UA122564C2/uk unknown
- 2015-09-18 CA CA2962075A patent/CA2962075A1/en active Pending
- 2015-09-18 DK DK15782109.1T patent/DK3198033T3/da active
- 2015-09-18 KR KR1020177010946A patent/KR102470456B1/ko active IP Right Grant
- 2015-09-18 EA EA201790716A patent/EA037920B1/ru unknown
- 2015-09-18 WO PCT/US2015/050996 patent/WO2016048833A2/en active Application Filing
- 2015-09-22 JO JOP/2015/0238A patent/JO3681B1/ar active
- 2015-09-24 TW TW104131544A patent/TWI706136B/zh active
- 2015-09-24 AR ARP150103070A patent/AR102345A1/es unknown
- 2015-09-25 UY UY0001036325A patent/UY36325A/es active IP Right Grant
-
2017
- 2017-03-19 IL IL251264A patent/IL251264B/en unknown
- 2017-03-24 PH PH12017500556A patent/PH12017500556A1/en unknown
- 2017-03-24 NI NI201700035A patent/NI201700035A/es unknown
- 2017-03-24 GT GT201700059A patent/GT201700059A/es unknown
- 2017-03-24 SV SV2017005415A patent/SV2017005415A/es unknown
- 2017-03-24 MX MX2022006536A patent/MX2022006536A/es unknown
- 2017-04-12 CO CONC2017/0003528A patent/CO2017003528A2/es unknown
- 2017-04-25 ZA ZA2017/02899A patent/ZA201702899B/en unknown
- 2017-04-26 EC ECIEPI201725787A patent/ECSP17025787A/es unknown
-
2018
- 2018-09-19 US US16/136,201 patent/US20190078166A1/en active Pending
-
2020
- 2020-03-10 JP JP2020040708A patent/JP7051920B2/ja active Active
-
2021
- 2021-11-30 AU AU2021277633A patent/AU2021277633A1/en active Pending
-
2022
- 2022-03-23 IL IL291633A patent/IL291633A/en unknown
- 2022-03-30 JP JP2022056709A patent/JP2022109910A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500556A1 (en) | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor | |
| PH12019502710A1 (en) | Fgfr2 inhibitors for the treatment of cholangiocarcinoma | |
| PH12019501942A1 (en) | Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor | |
| MX356802B (es) | Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf. | |
| TW201614237A (en) | Markers for identifying patients responsive to anti-PD-L1 antibody therapy | |
| MX365421B (es) | Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf. | |
| AU2015308620A8 (en) | Early lung cancer detection by DNA methylation phenotyping of sputum-derived cells | |
| MX2017007656A (es) | Uso de los inhibidores de pan fgfr y metodo para identificacion de pacientes con cancer elegibles para el tratamiento con un inhibidor de pan fgfr. | |
| MX2016004212A (es) | Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas. | |
| EP3860622A4 (en) | Methods for treating cancer with double stranded rna sensor activators and adoptive cell therapy | |
| PH12021550628A1 (en) | Treatment of cholangiocarcinoma | |
| EA201992849A1 (ru) | Ингибиторы fgfr2 для лечения холангиокарциномы | |
| PL408727A1 (pl) | Zestaw diagnostyczny i sposób jednoczesnego wykrywania mutacji w obrębie genu NF1 dla grupy pacjentów z podejrzeniem choroby Recklinghausena |